These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 26319201)
1. Enhancement of arabinocytosine (AraC) toxicity to AML cells by a differentiation agent combination. Wang X; Harrison JS; Studzinski GP J Steroid Biochem Mol Biol; 2016 Nov; 164():72-78. PubMed ID: 26319201 [TBL] [Abstract][Full Text] [Related]
2. The role of VDR and BIM in potentiation of cytarabine-induced cell death in human AML blasts. Harrison JS; Wang X; Studzinski GP Oncotarget; 2016 Jun; 7(24):36447-36460. PubMed ID: 27144333 [TBL] [Abstract][Full Text] [Related]
3. Differentiation agents increase the potential AraC therapy of AML by reactivating cell death pathways without enhancing ROS generation. Wang X; Dawod A; Nachliely M; Harrison JS; Danilenko M; Studzinski GP J Cell Physiol; 2020 Jan; 235(1):573-586. PubMed ID: 31245853 [TBL] [Abstract][Full Text] [Related]
4. Optimal AraC-Cytotoxicity to AML Cells Requires ERK5 Activity. Zheng R; Studzinski GP J Cell Biochem; 2017 Jun; 118(6):1583-1589. PubMed ID: 27922189 [TBL] [Abstract][Full Text] [Related]
5. Involvement of microRNA181a in differentiation and cell cycle arrest induced by a plant-derived antioxidant carnosic acid and vitamin D analog doxercalciferol in human leukemia cells. Duggal J; Harrison JS; Studzinski GP; Wang X Microrna; 2012; 1(1):26-33. PubMed ID: 25048087 [TBL] [Abstract][Full Text] [Related]
6. Participation of vitamin D-upregulated protein 1 (TXNIP)-ASK1-JNK1 signalosome in the enhancement of AML cell death by a post-cytotoxic differentiation regimen. Wang X; Nachliely M; Harrison JS; Danilenko M; Studzinski GP J Steroid Biochem Mol Biol; 2019 Mar; 187():166-173. PubMed ID: 30508644 [TBL] [Abstract][Full Text] [Related]
7. Novel analogs of 1,25-dihydroxyvitamin D Nachliely M; Sharony E; Kutner A; Danilenko M J Steroid Biochem Mol Biol; 2016 Nov; 164():59-65. PubMed ID: 26365556 [TBL] [Abstract][Full Text] [Related]
8. Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells. Pigneux A; Mahon FX; Uhalde M; Jeanneteau M; Lacombe F; Milpied N; Reiffers J; Belloc F Exp Hematol; 2008 Dec; 36(12):1648-59. PubMed ID: 18922616 [TBL] [Abstract][Full Text] [Related]
9. Prodifferentiation Activity of Novel Vitamin D₂ Analogs PRI-1916 and PRI-1917 and Their Combinations with a Plant Polyphenol in Acute Myeloid Leukemia Cells. Nachliely M; Sharony E; Bolla NR; Kutner A; Danilenko M Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27399677 [TBL] [Abstract][Full Text] [Related]
10. BRAF signals to pro-apoptotic BIM to enhance AraC cytotoxicity induced in AML cells by Vitamin D-based differentiation agents. Wang X; Harrison JS; Studzinski GP J Steroid Biochem Mol Biol; 2017 Oct; 173():139-147. PubMed ID: 27637326 [TBL] [Abstract][Full Text] [Related]
11. Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis. Chromik J; Safferthal C; Serve H; Fulda S Cancer Lett; 2014 Mar; 344(1):101-109. PubMed ID: 24184825 [TBL] [Abstract][Full Text] [Related]
12. JNK1 as a signaling node in VDR-BRAF induction of cell death in AML. Wang X; Beute WK; Harrison JS; Studzinski GP J Steroid Biochem Mol Biol; 2018 Mar; 177():149-154. PubMed ID: 28765039 [TBL] [Abstract][Full Text] [Related]
13. Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis. Liu N; Wang C; Wang L; Gao L; Cheng H; Tang G; Hu X; Wang J Int J Mol Med; 2016 Jun; 37(6):1686-96. PubMed ID: 27082972 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine. Visser N; Lourens HJ; Huls G; Bremer E; Wiersma VR Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33652766 [TBL] [Abstract][Full Text] [Related]
15. Enhanced autophagy in cytarabine arabinoside-resistant U937 leukemia cells and its potential as a target for overcoming resistance. Cheong JW; Kim Y; Eom JI; Jeung HK; Min YH Mol Med Rep; 2016 Apr; 13(4):3433-40. PubMed ID: 26935591 [TBL] [Abstract][Full Text] [Related]
16. Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia. Caldwell JT; Edwards H; Buck SA; Ge Y; Taub JW Pediatr Blood Cancer; 2014 Oct; 61(10):1767-73. PubMed ID: 24962331 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells. Nishioka C; Ikezoe T; Yang J; Yokoyama A Apoptosis; 2009 Sep; 14(9):1108-20. PubMed ID: 19548087 [TBL] [Abstract][Full Text] [Related]
18. Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage. Xie C; Edwards H; Caldwell JT; Wang G; Taub JW; Ge Y Mol Oncol; 2015 Feb; 9(2):409-21. PubMed ID: 25308513 [TBL] [Abstract][Full Text] [Related]
19. Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells. Ma J; Li X; Su Y; Zhao J; Luedtke DA; Epshteyn V; Edwards H; Wang G; Wang Z; Chu R; Taub JW; Lin H; Wang Y; Ge Y Sci Rep; 2017 Feb; 7():41950. PubMed ID: 28176818 [TBL] [Abstract][Full Text] [Related]
20. Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia. Österroos A; Kashif M; Haglund C; Blom K; Höglund M; Andersson C; Gustafsson MG; Eriksson A; Larsson R Biochem Pharmacol; 2016 Oct; 118():40-49. PubMed ID: 27565890 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]